
Erlons 150mg Tablet
Marketer
Fresenius Kabi India Pvt Ltd
Salt Composition
Erlotinib (150mg)
Overview Erlons 150mg Tablet
Erlons 150mg tablets treat non-small cell lung and pancreatic cancers. Administer this medication on an empty stomach, or at least one hour before or two hours after eating. Continue treatment as directed by your physician; duration depends on individual response. Follow your doctor's instructions precisely; incorrect usage or overdosage can cause severe adverse effects. Benefits may take weeks or months to appear; don't discontinue without consulting your doctor. Common side effects include nausea, vomiting, tiredness, skin rash, and weight loss. Severe diarrhea requires increased fluid intake or medical attention. Photosensitivity may occur; wear protective clothing and sunscreen outdoors. Report mouth sores, vision changes, or breathing problems immediately. Your doctor may monitor liver function regularly. Inform your healthcare provider of all other medications you're taking, as interactions are possible. This medicine is contraindicated during pregnancy and breastfeeding; reliable contraception is crucial for both partners. Smoking cessation is recommended during treatment. If taking antacids or other medications, allow at least a two-hour interval after taking Erlons 150mg.
Primary Ingredients of Erlons 150mg Tablet
No information provided. Please provide the text you wish me to rephrase.
Uses of Erlons 150mg Tablet
Cancers of the pancreas and non-small cell lung
Major Benefits of Erlons 150mg Tablet:
Consume this medication precisely as prescribed by your physician, adhering to the recommended dosage and treatment period. Ingest the 150mg Erlons Tablet whole; avoid chewing, crushing, or fracturing it. Administer on an empty stomach.
Common Side effects of Erlons 150mg Tablet:
- Abdominal pain
- Bone pain
- Breathlessness
- Constipation
- Cough
- Diarrhea
- Fatigue
- Fever
- Infection
- Muscle pain
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Vomiting
- Weight loss
How to use Erlons 150mg Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the 150mg Erlons Tablet whole; do not break, crush, or chew it. Administer on an empty stomach.
How Erlons 150mg Tablet works:
Ergons 150mg tablets combat lung cancer by targeting epidermal growth factor receptors (EGFR). These receptors, present on the surface of lung cancer cells, regulate cellular growth. The medication's mechanism involves binding to EGFR, thus blocking the cancer-promoting signals these receptors transmit and consequently hindering tumor expansion.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
The interaction between alcohol and Erlons 150mg Tablet is not established. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Using Erlons 150mg tablets during pregnancy poses a confirmed risk to the fetus. Prescribing may occur exceptionally in life-threatening cases where potential benefits outweigh risks. Physician consultation is essential.
Breast feedingCONSULT YOUR DOCTOR
Use of Erlons 150mg tablets while breastfeeding is likely inadvisable. Available human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingCONSULT YOUR DOCTOR
Driving ability while taking Erlons 150mg Tablets is undetermined. Refrain from driving if experiencing symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
For individuals with kidney impairment, Erlons 150mg tablets are considered safe, and no dosage modification is necessary. However, their use is contraindicated in patients experiencing severe kidney disease.
LiverCAUTION
Individuals with hepatic impairment should exercise caution when using Erlons 150mg tablets. Dosage modification may be necessary. Physician consultation is recommended.
What if you forget to take Erlons 150mg Tablet :
Omit any missed Erlons 150mg Tablet dose and resume your regular medication schedule. Avoid taking a double dose.
Facts to Know About Erlons 150mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Quinazoline-based Compound |
| Developing Habits | No. |
| Treatment Category | Cancer Treatments |
